Kidney Disease: Improving Global Outcomes (KDIGO)

Home

Guidelines for Transplantation
Guideline Organization	Sub-topic
CARI-Australia CMV Disease and Kidney Transplantation (2004)	CMV Disease and Kidney Transplantation Diagnostic tests for cytomegalovirus in renal transplantation Prophylaxis for cytomegalovirus infection in patients following renal transplantation Pre-emptive treatment of cytomegalovirus Treatment of cytomegalovirus disease in renal transplant recipients
Deceased Kidney Donor Suitability (2005)	Deceased Kidney Donor Suitability Non-heart beating donors Donors with sub-optimal renal function/structure Donor cancer Donor sepsis
Calcineurin Inhibitors in Renal Transplantation (2007)	Calcineurin Inhibitors in Renal Transplantation Adverse effects IL2R as induction therapy Nephrotoxicity and CNIs Outcomes related to CNIs Paediatric CNI Guidelines Pregnancy and lactation Therapeutic drug monitoring
Living Kidney Donors (2007) Draft - Under development	Living Kidney Donors Donor specific transfusions Justification for living donor kidney transplantation Potential child bearing donors Psychosocial care of living kidney donors
CSN-Canada
EBPG-Europe European Best Practice Guidelines for Renal Transplantation Part 1: 2000 Sections I-III Part 2: 2002 Section IV	EVALUTION, SELECTION, & PREPARATION OF POTENTIAL TRANSPLANT RECIPIENT Epidemiological data concerning end-stage renal failure (ESRF) and its treatment in Europe General evaluation Information for the transplant recipient Contra-indications for transplantation Risk factors/relative contra-indications Work-up for cancer and waiting time for pre-existing cancer Infectious risk Recurrence of original renal disease Work-up and preventive measures for thrombotic complications Co-morbid conditions Individual risk factors Immunogenetic work-up of the recipient (and donor) ABO blood grouping and HLA typing Antibody screening to evaluate sensitization status Pre-emptive transplantation Waiting list Assignment to the transplant waiting list Regular check-up while on waiting list Principals of organ sharing Pre-operative transfusion Specific groups Simultaneous transplantation of kidney and pancreas Combined transplants with liver, heart and lung Retransplants EVALUATION AND SELECTION OF DONORS Cadaveric heart-beating donors Selection of donors Determination of brain death Support of the potential donor and optimization of organ function Cadaveric non-heart beating donors Living kidney donors Related living kidney donors Unrelated living kidney donors Immunogenetic work-up of the donor THE TRANSPLANT RECIPIENT FROM INITIAL TRANSPLANT HOSPITALIZATION TO 1 YEAR POST-TRANSPLANT Cross-matching donor/recipient ABO blood group matching HLA matching and mismatching Pre-transplant antibody cross-matching Post-transplant antibody monitoring Pre-transplant dialysis/volume correction Prophylactic immunosuppression with biological agents (also called induction therapy) Initial and maintenance immunosuppressive treatment Evaluation of renal transplant patients and their grafts in the first post-transplant year Evaluation of patients with delayed graft function Evaluation of the patient with fever Infectious complications Cytomegalovirus (CMV) infection Hepatitis B virus infection Hepatitis C virus infection Rejection: Diagnosis and treatment Clinical and pathological diagnosis of acute rejection Treatment of acute rejection episodes Standards of graft and patient survival LONG-TERM MANAGEMENT OF THE TRANSPLANT RECIPIENT Organization of follow-up of transplant recipients after the first year Chronic graft dysfunction Differential diagnosis of chronic graft dysfunction Immunological factors (alloimmunity) Non-alloimmune factors De novo renal disease after transplantation Late recurrence of primary glomerulonephritides Late recurrence of other diseases Long-term immunosuppression Late steroid or cyclosporine withdrawal Therapy conversion Toxicity of immunosuppression Non-compliance Cardiovascular risks Cardiovascular disease after renal transplantation Arterial hypertension Hyperlipidaemia Post-transplant diabetes mellitus Hyperhomocysteinaemia Smoking Obesity and weight gain Immunosuppressive therapy Other risk factors Cancer risk after renal transplantation Post-transplant lymphoproliferative disease (PTLD): prevention and treatment Skin cancers: prevention and treatment Solid organ cancers: prevention and treatment Late infections Pneumocystis carinii pneumonia Tuberculosis Bone disease Haematological complications Anaemia Leukopenia Erythrocytosis Pregnancy in renal transplant recipients Paediatrics (specific problems) Elderly (specific problems) Analysis of patient and graft survival
KDOQI-US Anemia in Chronic Kidney Disease (2006)	Clinical Practice Recommendations for Anemia in Chronic Kidney Disease in Transplant Recipients
Bone Metabolism and Disease in Chronic Kidney Disease 2003	Bone Disease in the Kidney Transplant Recipient
Bone Metabolism and Disease in Chronic Kidney Disease in Children 2005	Bone Disease in the Pediatric Kidney Transplant Recipient
Hypertension and Antihypertensive Agents in Chronic Kidney Disease 2006	Pharmacological Therapy: Kidney Disease in the Kidney Transplant Recipient
UK-Renal Association Module 4: Transplantation2007 Module 2: Complications 2007	Transplantation Summary of Clinical Practice Guidelines Access to Renal Transplantation TX 1.1-1.8 Evaluation, Selection and Preparation of the Potential Transplant Recipient TX 2.1-2.9 Cardiovascular Disease: 1.9 Hypertension in renal transplant patients
National Institute for Health and Clinical Excellence (NICE) – United Kingdom	Immuno-suppressive regimens (adults) Immuno-suppressive regimens (children and adolescents)

Mission Statement: